Spotlight: Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry
American government agency, the Food and Drug Administration (FDA) releases nonbinding recommendations to psychedelic drug manufacturers
https://www.fda.gov/media/169694/download
Guidance for Industry
Psychedelic Drugs: Considerations for Clinical Investigations
Center for Drug Evaluation and Research
This final guidance provides general considerations for sponsors developing psychedelic drugs for the treatment of medical conditions (e.g., psychiatric disorders, substance use disorders) and discusses recommendations for clinical investigations using psychedelic drugs.
Psychedelic Drugs
FDA is supporting the development of psychedelic drugs, including new treatments for serious mental health conditions.
Center for Drug Evaluation and Research